Locations Main Campus: Chesterfield, MO 63017   |   Locations
314-434-1500 314-434-1500   |   Contact Us

Multimedia Encyclopedia

E-mail Form
Email Results


Prostate cancer screening

Prostate cancer screening - PSA; Prostate cancer screening - digital rectal exam; Prostate cancer screening - DRE


Cancer screenings can help find signs of cancer early, before you notice any symptoms. In many cases, finding cancer early makes it easier to treat or cure. However, at present it is not clear if screening for prostate cancer is helpful for most men. For this reason, you should speak with your health care provider before having a prostate cancer screening.

Types of Screenings


Prostate-specific antigen (PSA) test is a blood test that checks the level of PSA in your blood.

  • In some cases, a high level of PSA could mean you have prostate cancer.
  • But other conditions can also cause a high level, such as infection in the prostate or an enlarged prostate . You may need another test to find out if you have cancer.
  • Other blood tests or a prostate biopsy can help diagnose a cancer if the PSA test is high.

Digital rectal exam  (DRE) is a test where your provider inserts a lubricated, gloved finger into your rectum. This allows the provider to check the prostate for lumps or unusual areas. Unfortunately, most cancers cannot be felt with this type of exam, at least in the early stages.

In most cases, the PSA and DRE are done together.

Imaging tests such as an ultrasound or an MRI do not do an accurate job of screening for prostate cancer.


Benefits and Risks of Screenings


The benefit of any cancer screening test is to find cancer early, when it easier to treat. But the value of PSA screening for prostate cancer is debated. No single answer fits all men.

Prostate cancer often grows very slowly. PSA levels can begin to rise years before a cancer causes any symptoms or problems. It is also very common as men age. In many cases, the cancer will not cause any problems or shorten a man's life span.

For these reasons, it is not clear if the benefits of routine screenings outweigh the risks or side effects of being treated for prostate cancer once it is found.

There are other factors to think about before having a PSA test:

  • Anxiety. Elevated PSA levels do not always mean you have cancer. These results and the need for further testing can cause a lot of fear and anxiety, even if you do not have prostate cancer.
  • Side effects from further testing. If your PSA test is higher than normal, you may need to have a one or more biopsies to find out for sure. A biopsy is safe but can cause problems such as an infection, pain, fever, or blood in the semen or urine.
  • Overtreatment. Many prostate cancers will not affect your normal life span. But since it is impossible to know for sure, most people want to get treatment. Cancer treatment can have serious side effects, including problems with erections and urinating. These side effects can cause more problems than the untreated cancer.


Who Needs Screenings


Measuring the PSA level can increase the chance of finding prostate cancer when it is very early. But there is debate over the value of the PSA test for detecting prostate cancer. No single answer fits all men.

Before having the test, talk to your provider about the pros and cons of having a PSA test. Ask about:

  • Whether screening decreases your chance of dying from prostate cancer.
  • Whether there is any harm from prostate cancer screening, such as side effects from testing or overtreatment of cancer when discovered.

If you choose to be tested, the PSA is most often done every year to screen men:

  • From ages 55 to 69, if no risk factors are present.
  • Starting around age 40 to 45 if they have a higher chance of developing prostate cancer. A family history of prostate cancer (especially a brother or father) and being African American are more common risk factors.




Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int . 2013;112(5):543-547. PMID: 23924423 www.ncbi.nlm.nih.gov/pubmed/23924423 .

Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med . 2012;157(2):120-134. PMID: 22801674 www.ncbi.nlm.nih.gov/pubmed/22801674 .

National Cancer Institute. Prostate Cancer Screening (PDQ)-Health Professional Version. Updated March 4, 2016. www.cancer.gov/types/prostate/hp/prostate-screening-pdq#section/all . Accessed October 12, 2016.

Nelson WG, Carter HB, DeWeese TL, Antonarakis ES, Eisenberger MA. Prostate cancer. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology . 5th ed. Philadelphia, PA: Elsevier Saunders; 2014:chap 84.

Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin . 2014;64(1):30-51. PMID: 24408568 www.ncbi.nlm.nih.gov/pubmed/24408568 .


        A Closer Look


        Talking to your MD


          Self Care


            Tests for Prostate cancer screening



            Review Date: 8/15/2016

            Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.

            The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.




            A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.

            Content is best viewed in IE9 or above, Firefox and Google Chrome browser.